InfuSystem Holdings, Inc. (NYSE:INFU) CEO Sells 20,000 Shares of Stock

InfuSystem Holdings, Inc. (NYSE:INFU) CEO Richard Dilorio sold 20,000 shares of the firm’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $9.32, for a total value of $186,400.00. Following the transaction, the chief executive officer now directly owns 436,659 shares of the company’s stock, valued at approximately $4,069,661.88. This represents a 4.38 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Richard Dilorio also recently made the following trade(s):

• On Wednesday, November 27th, Richard Dilorio sold 5,398 shares of InfuSystem stock. The shares were sold at an average price of $8.87, for a total value of $47,880.26.

InfuSystem Stock Performance

InfuSystem stock traded down $0.10 during mid-day trading on Wednesday, reaching $8.85. The stock had a trading volume of 39,965 shares, compared to its average volume of 60,063. The stock has a market cap of $188.15 million, a price-to-earnings ratio of 147.52 and a beta of 1.45. InfuSystem Holdings, Inc. has a fifty-two week low of $5.74 and a fifty-two week high of $10.99. The company has a 50-day simple moving average of $7.29. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.98 and a quick ratio of 1.59.

Analysts Set New Price Targets

INFU has been the topic of a number of recent analyst reports. StockNews.com raised InfuSystem from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 8th. B. Riley began coverage on shares of InfuSystem in a research report on Thursday, September 26th. They set a “buy” rating and a $13.00 price objective for the company.

Institutional Trading of InfuSystem

Hedge funds and other institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets raised its position in InfuSystem by 66.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 4,076 shares of the company’s stock valued at $27,000 after buying an additional 1,626 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of InfuSystem by 13.8% in the second quarter. Rhumbline Advisers now owns 17,658 shares of the company’s stock valued at $121,000 after purchasing an additional 2,145 shares during the last quarter. State Street Corp lifted its position in shares of InfuSystem by 1.1% during the third quarter. State Street Corp now owns 267,012 shares of the company’s stock valued at $1,789,000 after purchasing an additional 3,019 shares in the last quarter. ARS Investment Partners LLC boosted its holdings in InfuSystem by 11.4% during the second quarter. ARS Investment Partners LLC now owns 33,510 shares of the company’s stock worth $229,000 after purchasing an additional 3,422 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its position in InfuSystem by 6.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 93,899 shares of the company’s stock worth $641,000 after purchasing an additional 5,391 shares in the last quarter. Institutional investors own 71.13% of the company’s stock.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.